Curtis Oltmans, JD joined Fulcrum as General Counsel in November 2020 with over 25 years of experience in
corporate law including senior management positions in legal departments at several leading
pharmaceutical and biotechnology companies. He most recently served as Vice President, Head of
Litigation at DaVita Kidney Care, Inc. where he led a 30-person team and was responsible for all
litigation, workers’ compensation and employee safety matters. Prior to DaVita, Curtis was Executive
Vice President, General Counsel and Corporate Secretary at Array BioPharma Inc. where he oversaw all
legal, corporate governance, patent and compliance matters. He previously served as Corporate Vice
President and General Counsel for Novo Nordisk, Inc., North America where he was responsible for
strategic support in areas including market access, government affairs, communications and product
marketing. He has also served as Assistant General Counsel for Eli Lilly and Company after beginning his
legal career supporting clients in pharmaceutical and medical device litigation matters. Curtis received a
BA in political science from the University of Nebraska and his JD from the University of Nebraska
College of Law.
What is Curtis Gale Oltmans' net worth?
The estimated net worth of Curtis Gale Oltmans is at least $7,681.28 as of June 28th, 2021. Mr. Oltmans owns 1,088 shares of Fulcrum Therapeutics stock worth more than $7,681 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Oltmans may own. Additionally, Mr. Oltmans receives a salary of $83,980.00 as SVP at Fulcrum Therapeutics. Learn More about Curtis Gale Oltmans' net worth.
How old is Curtis Gale Oltmans?
What is Curtis Gale Oltmans' salary?
How do I contact Curtis Gale Oltmans?
Has Curtis Gale Oltmans been buying or selling shares of Fulcrum Therapeutics?
Curtis Gale Oltmans has not been actively trading shares of Fulcrum Therapeutics during the last ninety days. Most recently, on Monday, June 28th, Curtis Gale Oltmans bought 1,088 shares of Fulcrum Therapeutics stock. The stock was acquired at an average cost of $9.01 per share, with a total value of $9,802.88. Following the completion of the transaction, the senior vice president now directly owns 1,088 shares of the company's stock, valued at $9,802.88. Learn More on Curtis Gale Oltmans' trading history.
Who are Fulcrum Therapeutics' active insiders?
Are insiders buying or selling shares of Fulcrum Therapeutics?
During the last year, insiders at the sold shares 2 times. They sold a total of 5,094 shares worth more than $57,935.58. The most recent insider tranaction occured on March, 8th when VP Greg Tourangeau sold 4,884 shares worth more than $57,240.48. Insiders at Fulcrum Therapeutics own 2.5% of the company.
Learn More about insider trades at Fulcrum Therapeutics. Information on this page was last updated on 3/8/2024.
